Cargando…
New drugs in prostate cancer
The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel...
Autores principales: | Yoo, Sangjun, Choi, Se Young, You, Dalsan, Kim, Choung-Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Pacific Prostate Society
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916061/ https://www.ncbi.nlm.nih.gov/pubmed/27358841 http://dx.doi.org/10.1016/j.prnil.2016.05.001 |
Ejemplares similares
-
Width of spared neurovascular bundle after robot-assisted laparoscopic prostatectomy in patients with prostate cancer: is it a reliable factor for predicting postoperative sexual outcome?
por: Yoo, Sagnjun, et al.
Publicado: (2021) -
Role of Radical Prostatectomy for High-Risk Prostate Cancer
por: You, Dalsan, et al.
Publicado: (2010) -
Luteinizing Hormone Levels Relate to the Unfavorable Pathology of Prostate Cancer
por: Choi, Se Young, et al.
Publicado: (2020) -
A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways
por: Kim, Yunlim, et al.
Publicado: (2023) -
Does Radical Cystectomy Improve Overall Survival in Octogenarians with Muscle-Invasive Bladder Cancer?
por: Yoo, Sangjun, et al.
Publicado: (2011)